Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024

Core Insights - Ocugen, Inc. is hosting a Clinical Showcase on November 12, 2024, to present updates on its ongoing gene therapy trials for various retinal diseases [1][2] - The event will feature updates on the Phase 3 liMeliGhT clinical trial for retinitis pigmentosa, preliminary data from the Phase 1/2 OCU410 ArMaDa trial for geographic atrophy, and progress from the Phase 1/2 OCU410ST GARDian study for Stargardt disease [2][3] - Ocugen plans to initiate the Phase I clinical trial for its biologic candidate OCU200 for diabetic macular edema within the current quarter [2] Event Details - The Clinical Showcase will take place at the Nasdaq MarketSite in Times Square, New York City, from 10 a.m. to noon ET [1] - Presenters will include key executives and study investigators, providing insights into the clinical trials and patient experiences [3] Company Overview - Ocugen, Inc. focuses on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines aimed at improving health and addressing unmet medical needs [5] - The company is advancing research in multiple areas, including retinal diseases and infectious diseases, leveraging its breakthrough modifier gene therapy platform [5]